Sagent Pharmaceuticals, Inc. ("Sagent") is a manufacturer of pharmaceutical injectables and biosimilars.

According to a law firm's press release, on July 10, 2016, Sagent’s Board of Directors caused Sagent to enter into an agreement and plan of merger with Nichi-Iko Pharmaceutical Co., Ltd. and its subsidiary Shepard Vision, Inc. (the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, stockholders of Sagent will receive $21.75 per share in cash. The Complaint alleges that on August 1, 2016, Defendants issued materially incomplete and misleading disclosures in the Solicitation/Recommendation Statement filed on Schedule 14D-9 (the “Solicitation Statement”) filed with the United States Securities and Exchange Commission in connection with the Proposed Transaction. According to the Complaint, the Solicitation Statement is deficient and misleading in that it fails to provide adequate disclosure of all material information related to the Proposed Transaction.

This case was voluntarily dismissed on October 5, 2016 as a result of a settlement reached in a related state action filed in the Circuit Court of Cook County, Illinois, Chancery Division under Docket No. 2016-CH-10413.